Overview

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Status:
Completed
Trial end date:
2019-11-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Nerre Therapeutics Ltd.
Collaborator:
Nerre Therapeutics Ltd.